コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 dney disease-associated ApoL1 variants lysed Trypanosoma brucei rhodesiense.
2 in cytokine gene knockout mice infected with Trypanosoma brucei rhodesiense.
3 roove binders was evaluated in vitro against Trypanosoma brucei rhodesiense (8 compounds) and Plasmod
4 Rhodesain is a major cysteine protease of Trypanosoma brucei rhodesiense, a pathogen causing Human
5 n the host immune response to infection with Trypanosoma brucei rhodesiense, a protozoan parasite res
6 ural product displayed high activity against Trypanosoma brucei rhodesiense, a recalcitrant parasite
7 ei isolate, and several clinical isolates of Trypanosoma brucei rhodesiense (agent of east African sl
8 ition of the cysteine proteases rhodesain of Trypanosoma brucei rhodesiense and falcipain-2 of Plasmo
9 .045 muM against the human pathogenic strain Trypanosoma brucei rhodesiense and is more than 4000 tim
10 brucei , Trypanosoma brucei gambiense , and Trypanosoma brucei rhodesiense and is one of Africa's ol
11 logues possess micromolar activities against Trypanosoma brucei rhodesiense and Leishmania donovani a
12 tent inhibitory effect against the parasites Trypanosoma brucei rhodesiense and Leishmania donovani w
13 wed promising in vitro activity against both Trypanosoma brucei rhodesiense and Plasmodium falciparum
16 ican human African trypanosomiasis caused by Trypanosoma brucei rhodesiense and the West African form
17 t cause human African Trypanosomiasis (HAT), Trypanosoma brucei rhodesiense and Trypanosoma brucei ga
19 The expansion of sleeping sickness caused by Trypanosoma brucei rhodesiense beyond its traditional fo
20 ent manner and demonstrated activity against Trypanosoma brucei rhodesiense bloodstream forms, which
22 ainst cultured Trypanosoma brucei brucei and Trypanosoma brucei rhodesiense cells with ED(50) values
23 gnized as a strong inhibitor of rhodesain of Trypanosoma brucei rhodesiense, endowed with a k(second)
25 r proteins that contribute to virulence, and Trypanosoma brucei rhodesiense EVs contain the serum res
26 The bloodstream trypanosome clone MVAT4 of Trypanosoma brucei rhodesiense expresses a metacyclic vs
28 ch as Plasmodium falciparum, Lassa Virus and Trypanosoma brucei rhodesiense, has resulted in elevated
29 iprotozoal assays, ten of the oils inhibited Trypanosoma brucei rhodesiense (IC(50) 15.9-64.5 mug/mL)
30 furan were synthesized and evaluated against Trypanosoma brucei rhodesiense in the STIB900 mouse mode
31 rface glycoprotein (VSG) gene in bloodstream Trypanosoma brucei rhodesiense involves a duplicative tr
33 subspecies, Trypanosoma brucei gambiense and Trypanosoma brucei rhodesiense, is a parasitic disease t
34 -stage HAT, and the only drug for late-stage Trypanosoma brucei rhodesiense, is intravenous melarsopr
35 s on the proliferation of Trypanosoma cruzi, Trypanosoma brucei rhodesiense, Leishmania donovani, Tox
36 To address this hypothesis, we transformed Trypanosoma brucei rhodesiense LouTat 1 with the 117 VSG
37 stance to most African trypanosomes, but not Trypanosoma brucei rhodesiense or T.b. gambiense, which
38 ckness, is caused by the protozoan parasites Trypanosoma brucei rhodesiense or Trypanosoma brucei gam
39 or in vitro antiprotozoal activities against Trypanosoma brucei rhodesiense, Plasmodium falciparum, a
40 otozoal activities of compounds 1-60 against Trypanosoma brucei rhodesiense, Plasmodium falciparum, a
42 d and tested for in vitro activities against Trypanosoma brucei rhodesiense, Plasmodium falciparum, a
43 ir in vitro antiprotozoal properties against Trypanosoma brucei rhodesiense, Plasmodium falciparum, a
44 otozoal activities of compounds 1-43 against Trypanosoma brucei rhodesiense, Plasmodium falciparum, a
45 ve strategies for the sustainable control of Trypanosoma brucei rhodesiense (Rhodesian) sleeping sick
47 layed in vitro nanomolar IC50 values against Trypanosoma brucei rhodesiense STIB900 with selectivity
48 18b show IC50 values of 5 nM or less against Trypanosoma brucei rhodesiense (T. b. r.) and 10a, 10b,
49 3 isoxazole derivatives were assayed against Trypanosoma brucei rhodesiense (T. brucei rhodesiense) S
50 cribed, followed by their evaluation against Trypanosoma brucei rhodesiense, T. cruzi, Leishmania don
51 sed by Trypanosoma brucei gambiense (Tbg) or Trypanosoma brucei rhodesiense (Tbr), remains a signific
52 osomal cathepsin L-like cysteine protease of Trypanosoma brucei rhodesiense, the causative agent of H
53 ave additional trypanolytic activity against Trypanosoma brucei rhodesiense, the cause of acute Afric
54 rtant for early resistance to infection with Trypanosoma brucei rhodesiense, the extracellular protoz
55 orrelation with the human infective parasite Trypanosoma brucei rhodesiense, the most potent compound
56 ting against four other protozoan parasites: Trypanosoma brucei rhodesiense , Trypanosoma cruzi , Lei
57 st important human trypanosomatid pathogens (Trypanosoma brucei rhodesiense, Trypanosoma cruzi, and L
58 st important human trypanosomatid pathogens (Trypanosoma brucei rhodesiense, Trypanosoma cruzi, and L
59 growth inhibition of the bloodstream form of Trypanosoma brucei rhodesiense trypomastigotes by bispho
60 ctive (0.5 muM </= IC(50) < 6.0 muM) against Trypanosoma brucei rhodesiense trypomastigotes were 5-31
61 c markers in CSF from patients infected with Trypanosoma brucei rhodesiense, using 1H nuclear magneti
62 ite concentrations in patients infected with Trypanosoma brucei rhodesiense, using liquid chromatogra